ATLANTA, Aug. 21, 2025 — Verdata, a leader in proprietary commercial risk data and analytics, announced today an $8 million Series A financing led by Continental Investors, with participation from 1st & Main Growth Partners, Front Porch Venture Partners, Overline Venture Capital, and several industry leaders.

Verdata delivers verified cross-industry insights on business identity, financial stability, service reliability, and regulatory compliance. Its proprietary network of more than 20 million active U.S. businesses enables objective, scalable risk assessments—reducing manual intervention, mitigating fraud and compliance risks, and unlocking new revenue opportunities.

“Verdata is redefining how trust is established in B2B relationships,” said CEO Mike Mondelli. “This funding accelerates product innovation, strengthens support for our customers, and extends our reach across key industries.”

Verdata helps clients:

• Verify business and principal identities to combat fraud
• Ensure brand alignment to manage regulatory risk
• Prioritize high-impact workflows
• Drive revenue growth with confidence

Its solutions are used in SMB lending, POS financing, commercial insurance, and embedded finance to manage relationship risk and build lasting partnerships.

“Team Continental is pleased to lead this round,” said Paul Purcell, Principal at Continental Investors. “Verdata’s collaborative approach aggregates fragmented commercial data into proprietary insights that improve customer acquisition, decision-making, and industry-wide efficiency.”

About Verdata

Verdata helps embedded finance providers, SMB lenders, payment processors, medical financiers, and banks build trust in B2B relationships. Our platform automates partner assessments and delivers continuous monitoring to reduce fraud, compliance, and regulatory risks across the entire relationship lifecycle.

SOURCE Verdata

Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies

BOULDER, Colo., Aug. 20, 2025 — KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors.

The capital from this Series C close will fuel expansion of KROMATID’s proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy.

“We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology,” said Jim Chomas, CEO of KROMATID. “This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients.”

“KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry,” said Bill Snider, Partner at BroadOak Capital Partners. “We are proud to continue our partnership as they enter their next phase of growth.”

Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis.

About KROMATID
KROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval.

About BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit www.broadoak.com.

Media Contact:
Amanda Ladas
Global Marketing Manager
KROMATID
[email protected]
773-720-0709

SOURCE KROMATID

Pioneering Growth and Innovation in the Frozen Novelty Category

LONDON, Aug. 4, 2025 — Doughlicious®, the better-for-you frozen novelty brand known for its artisanal frozen cookie dough-enrobed gelato bites, indulgent flavors, and clean ingredients is thrilled to announce a major milestone in its journey: a $5 million fundraise round led by Rich Products Ventures (RPV), the corporate venture capital fund of global, family-owned food company Rich Products (Rich’s), and private investor collective The Angel Group, along with participation from existing investors.

This exciting fundraise marks a pivotal moment for Doughlicious as it accelerates its expansion across the U.S. and international markets. With a long track record of helping innovative food startups scale, gain a competitive edge and achieve their full potential, RPV brings deep category expertise and global distribution support. The Angel Group, a network of visionary investors with a passion for disruptive consumer brands, brings strategic counsel, access to influential networks, and a shared commitment to long-term growth.

“This partnership with Rich’s and The Angel Group is more than an investment—it’s a vote of confidence in the future of Doughlicious and our mission to redefine indulgence,” said Kathryn Bricken, Founder and CEO of Doughlicious. “With their support, we’re poised to grow faster, innovate smarter, and bring our crave-worthy creations to more consumers around the world.”

Doughlicious has already made a strong mark in retail, with distribution in major U.S. retailers including Target, Whole Foods, Wegmans, and GoPuff. The brand’s line of frozen gelato bites wrapped in cookie dough and dusted in cookie crumb are gluten-free, made with natural ingredients, and available in both full-size and mini formats, offering a modern twist on nostalgic favorites.

“Innovation is at the core of both Rich’s and RPV, and we believe in the bold ideas that are shaping the future of food,” said Dinsh Guzdar, managing partner of Rich Products Ventures. Doughlicious is a great example of a brand that is delivering on what today’s consumers want – smaller portions and clean-label offerings that don’t sacrifice on taste. We’re excited to help Doughlicious expand its footprint throughout the U.S. and shake up the freezer section with a new concept in permissible indulgence.”

Together, this dynamic trio—Doughlicious, Rich’s, and The Angel Group—are baking up something truly special. With innovation, passion, and strategic resources in the mix, Doughlicious is ready to take the frozen novelty dessert world by storm.

About Doughlicious The London Dough Co.:

Doughlicious is a proudly female-founded and operated business on a mission to redefine the cookie dough experience by creating the ultimate snackable treat. Focused on better-for-you ingredients and sustainable practices, the brand brings a fresh perspective to the frozen snack category. Doughlicious’ frozen cookie dough & gelato bites are certified gluten-free, free from added refined sugars and white bleached flour, and contain no artificial additives or preservatives. All frozen snacks are carefully crafted and produced at the brand’s facility in London, England. Doughlicious products are available in over 10,000 retail stores across the US, UK, parts of Europe and the Middle East. For more information, visit https://doughlicious.co.uk/, Instagram and TikTok.

Meet Rich’s:

Rich’s, also known as Rich Products Corporation, is a family-owned food company dedicated to inspiring possibilities. From cakes and icings to pizza, appetizers and specialty toppings, their products are used in homes, restaurants and bakeries around the world. Beyond great food, their customers also gain insights to help them stay competitive, no matter their size. Their portfolio includes creative solutions geared at helping food industry professionals compete in foodservice, retail, in-store bakery, deli, and prepared foods, among others. Working across 100 locations globally, with annual sales exceeding $5.8 billion, Rich’s is a global leader with a focus on everything that family makes possible. Rich’s®—Infinite Possibilities. One Family.

Rich Products Ventures (RPV) is the corporate venture capital arm of Rich Products. RPV invests in venture and growth stage companies that are shaping the future of food through technology and innovation, focusing on four core areas: nutrition and health, sustainable production, the next generation of retail and foodservice and dynamic supply chain. Offering a mix of operational expertise, strategic relationships, flexible capital and global reach, RPV helps startups scale, gain a competitive edge and achieve their full potential.

Learn more at www.Richs.com and www.richproductsventures.com or join the conversation on Facebook, Instagram, LinkedIn and Twitter.

Media Contacts: 
Whitney Spielfogel, Doughlicious
516-316-4201
[email protected]

Allie Friedman, Rich Products / Rich Products Ventures
716-479-3969
[email protected]

SOURCE Doughlicious®

In addition to the €10 million in non-dilutive financing obtained by Stellaria through its success in the France 2030 ‘Innovative Reactors’ call for projects, this funding will be used to finance all the technical and regulatory studies necessary to establish a first molten-salt facility capable of sustaining a fission reaction, scheduled for 2029.

Founded in 2023, Stellaria is developing the Stellarium, a fourth-generation molten-salt nuclear reactor capable of fully regenerating its fuel during operation. It will therefore be self-sufficient for more than 20 years, while reducing long-lived nuclear waste (minor actinides). The first production unit is expected to be offered for commercial deployment by 2035. Competitive, safe and flexible, the Stellarium will also help to decarbonise energy production, whether for industry or the grid. By replacing fossil fuel sources with Stellarium, it will be possible to cut CO2 and particulate emissions from industrial sites by 99%.

Thanks to this funding, Stellaria aims to double its workforce to accelerate R&D around its reactor and finalise the development of one of the world’s first liquid-core fast-neutron reactor demonstrators. This step will allow it to develop its research laboratory in Grenoble by several million euros, to continue its scientific and industrial collaborations, and submit an Application for Authorisation to Create (DAC) a Basic Nuclear Installation (INB) to the safety authorities for the construction of its prototype.

Nicolas Breyton, CEO of Stellaria, said: “This funding round demonstrates the confidence of investors in the technical maturity of our molten-salt reactor, which opens up a new path towards the circular economy of the fuel cycle. We are laying the foundations for a model in which electro-intensive industries become self-sufficient in energy throughout the lifetime of their facilities. This is a key step towards the sustainable reindustrialisation of our territory.”

PDF: https://mma.prnewswire.com/media/2737585/Stellaria_Nuclear_Reactor.pdf
Logo: https://mma.prnewswire.com/media/2737584/Stellaria_Logo.jpg 

Press contact:
Comclean
Anna Denysova
[email protected]

SOURCE Stellaria

Funding commitment makes Veralto a Cornerstone Investor of the new proposed fund, expected to launch in October

WALTHAM, Mass., July 22, 2025 — Veralto Corporation (NYSE: VLTO) (the “Company”), a global leader in essential water and product quality solutions dedicated to Safeguarding the World’s Most Vital Resources™, announced a €20 million investment commitment in Emerald Technology Ventures’ Global Water Fund II, reinforcing the Company’s focus on driving the next wave of water innovation and advancing breakthrough technologies that address critical global water challenges.

Headquartered in Zurich with offices in Toronto and Singapore, Emerald is one of the first venture capital firms to focus on sustainable industrial innovation, with more than €1.2 billion in assets under management.

Veralto’s investment gives the Company visibility and access to key early- and growth-stage water technology businesses that address the most complex challenges facing Veralto’s current customers. The investment also offers Emerald’s portfolio companies an opportunity to benefit from the Company’s strong customer intimacy, global market reach, and track record of successfully scaling innovative businesses.

“Emerald’s global presence and deep sector expertise provide Veralto with early insight into emerging water-focused ventures, making it a strong strategic partner to augment our innovation and technology development efforts,” said Jennifer L. Honeycutt, President and Chief Executive Officer at Veralto. “This move strengthens our ability to identify and scale solutions that align closely with our customers’ needs in addressing critical water challenges worldwide.”

“Veralto, as a leading global player in water analytics and treatment, is a natural partner for our next Global Water Fund,” said Dr. Helge Daebel, Partner and Head of Emerald’s Water Practice. “Their purpose aligns with our more than 25 years of investing in sustainable industrial transformation, and they will join the ranks of more than 50 large corporations that we already count as investors and partners in our open innovation efforts.”

Emerald’s €150-180 million Global Water Fund II, which will launch in October, is designed to accelerate innovation across the water value chain, including technologies that address treatment, monitoring and emerging contaminants. The new partnership reflects a shared mission to shape the future of water through innovation and collaboration.

ABOUT VERALTO
With annual sales of over $5 billion, Veralto is a global leader in essential technology solutions with a proven track record of solving some of the most complex challenges we face as a society. Our industry-leading companies with globally recognized brands help billions of people around the world access clean water, safe food and trusted essential goods. Headquartered in Waltham, Massachusetts, our global team of nearly 17,000 associates is committed to making an enduring positive impact on our world and united by a powerful purpose: Safeguarding the World’s Most Vital Resources™.

ABOUT EMERALD TECHNOLOGY VENTURES
Emerald is a globally recognized venture capital firm, founded in 2000, that manages and advises assets of over €1 billion from its offices in Zurich, Toronto and Singapore. The firm invests in start-ups that tackle big challenges in climate change and sustainability, with four current funds, hundreds of venture transactions and five third-party investment mandates, including loan guarantees to over 100 start-ups.

FORWARD-LOOKING STATEMENTS
Certain statements in this release, including the statements regarding Emerald Technology Ventures and its Water Fund, the Company’s differentiation and positioning to continue delivering sustainable, long-term shareholder value and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. All statements other than historical factual information are forward-looking statements, including, without limitation, statements regarding: projections of revenue, expenses, profit, profit margins, asset values, pricing, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, Veralto’s liquidity position or other financial measures; Veralto’s management’s plans and strategies for future operations, including statements relating to anticipated operating performance, customer demand, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, divestitures, spin-offs, split-offs, initial public offerings, other securities offerings or other distributions, strategic opportunities, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets Veralto sells into, including the impact of changes to global trade policies, restrictions on imports, related countermeasures and reciprocal tariffs; future, new or modified laws, regulations, accounting pronouncements or public policy changes; regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; results of operations and/or financial condition; general economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Veralto intends or believes will or may occur in the future. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

SOURCE Veralto

• Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials
• Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies
• Financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures

PARIS, July 17, 2025 — One Biosciences (“One Biosciences” or the “Company”), a precision oncology techbio company pioneering clinical grade single-cell tumor transcriptomic profiling, today announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding, to date, to over €20 million including Home Biosciences’ seed financing.

One Biosciences technology creates detailed functional profiles of patient tumors, unlocking insights that may drive better clinical decision-making, patient selection, therapy development, and potentially optimizing clinical trials. Proceeds from the financing will accelerate the clinical development of One Biosciences’ flagship OneMap™ platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies.

Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.”

Dr. Céline Vallot, Co-Founder of One Biosciences and group leader at Curie Institute, commented: “This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.” 

Dr Mehdi Touat, Assistant Professor, Assistance Publique – Hôpitaux de Paris AP-HP, Pitié-Salpêtrière and Paris Brain Institute, said: “Widespread use of next generation sequencing (NGS) profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyze the next generation of diagnostic and therapeutic advances “.

About One Biosciences

One Biosciences, founded by Dr. Céline Vallot, Curie Institute and Home Biosciences in 2020, is an AI driven single cell transcriptomic oncology solutions company that is pioneering clinical grade single-cell tumor transcriptomic profiling. We aim to help clinicians select optimal treatments for their patients by decoding tumor heterogeneity from standard clinical samples, while enabling pharmaceutical companies to improve clinical trial outcomes. One Biosciences has partnerships with Curie Institute, Gustave Roussy Institute and AP-HP and is supported by Medicen, PSCC and Matwin. The company is financed by Bpifrance, Région Ile de France, France 2030, Redmile Group Blast, Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures.

For more information, visit: www.onebiosciences.fr

SOURCE One Biosciences

The funding will fast-track EDGX’s mission to deliver the world’s fastest AI-powered edge computers for satellite constellations, enabling fast and efficient data processing from space

GHENT, Belgium, Aug. 11, 2025 — Belgian spacetech startup EDGX has closed a €2.3 million seed funding round to accelerate commercialisation of EDGX Sterna, the next generation edge AI computer for satellites.

The startup has also closed a multi-unit deal with a satellite operator worth €1.1 million and can already announce plans of an in-orbit demonstration on a SpaceX Falcon 9 mission in February 2026.

The funding round was co-led by the imec.istart future fund and, with participation from the Flanders Future Tech Fund, managed by the Flemish investment company PMV. EDGX has also attracted further funding from existing investor imec.istart, Europe’s top-ranked university-affiliated accelerator.

The EDGX Sterna Computer is a high-performance data processing unit (DPU) powered by NVIDIA technology. It provides the computational performance and AI acceleration needed to run complex algorithms directly in orbit. This capability eliminates the traditional bottleneck of sending massive raw datasets to Earth for processing, enabling satellite operators to deliver faster, more efficient, and data-driven services.

EDGX’s Sterna computer is powered by its SpaceFeather software stack, built for autonomous, resilient, and upgradeable satellite operations. It includes a space-hardened Linux OS with full traceability, a dedicated supervisory system for autonomous health monitoring, radiation fault detection and recovery, and an in-orbit application framework for deploying new capabilities post-launch.

Commenting on the news, Nick Destrycker, founder and CEO said: “Customers aren’t waiting for flight validation, they’re signing now. With a full launch manifest, secured commercial contracts, and our first mission set for Falcon 9, this funding enables us to scale to meet demand for real-time intelligence from space.”

Kris Vandenberk, managing partner at imec.istart future fund said: “EDGX represents exactly the kind of transformative infrastructure play we look for. The space industry is hitting a fundamental bottleneck; we’re generating massive amounts of data in orbit but still using outdated ‘store and forward’ architectures. EDGX is solving this by bringing AI-powered edge computing directly into space, enabling satellites to analyse and act on data in real-time rather than waiting for ground processing.”

Photo – https://mma.prnewswire.com/media/2746931/EDGX.jpg
Logo – https://mma.prnewswire.com/media/2746930/EDGX_Logo.jpg

SOURCE EDGX

NEW YORK, Aug. 20, 2025 — Vendelux, the global leader in event intelligence, has launched a delegate marketing platform to empower event organizers to grow their audiences with unmatched precision and speed.

Through its free Delegate Marketing Platform, Vendelux offers conference organizers direct access to data-driven tools, AI agents and workflows and a network of event marketers controlling more than $50 billion in event sponsorship budgets, reaching over 10 million event-attending professionals.

With Vendelux’s new delegate marketing platform, conference organizers can:

• Pinpoint and connect with high-value potential delegates and sponsors by using AI agents
• Access targeted attendee recommendations tailored to each organizer’s unique event audience segments
• Leverage insights from 250,000+ B2B events and tradeshows to identify and attract the right audience faster than ever

Proven Delegate Growth

Organizers using Vendelux’s agentic platform have already seen measurable gains:

• Stablecon, a new event from This Week In FinTech, sourced 23% of attendees from Vendelux’s Delegate Marketing Platform. “The platform was instrumental in helping us fill the room with the right people,” said Nik Milanovic, Founder of This Week In FinTech.
• HLTH credited Vendelux for a 6% boost of executive-level attendees at its Vive event. “It’s my secret weapon,” said Barry Edelman, Global Head of Marketing at HLTH.

A No-Cost AI-Powered Growth Engine

“The Delegate Marketing Platform empowers event organizers to fill their events with the best and most relevant attendees,” said Alex Reynolds, Co-Founder & CEO of Vendelux. “Event organizers can now leverage AI agents and insights to reach the audiences and budgets that will take their events to the next level – faster, smarter, and at zero cost.”

Event organizers can get started with the Delegate Marketing Platform to start growing their delegate base today at vendelux.com/event-organizers. Vendelux will also be represented at the Society of Independent Show Organizers (SISO) Leadership Summit in Indianapolis from August 19-21, 2025.

About Vendelux

Vendelux is the AI platform for events that helps conference organizers, event marketers, and attendees connect with the right people at the right events. With insights from over 250,000 global business conferences and trade shows, Vendelux enables smarter audience targeting, better networking, and data-driven event success. Vendelux is backed by leading investors such as FirstMark Capital and top event organizers including the founders of HLTH, ShopTalk, Money20/20, Manifest, HR Transform, InsureTech Connect, Blueprint, SaaStock and FTLive.

Learn more at Vendelux.com.

MEDIA CONTACT:
Tanya Peress
Head of Marketing
[email protected]

Related links: vendelux.com/event-organizers

BOSTON, Aug. 20, 2025 — Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures, following Somite’s $47M Series A closing led by Khosla Ventures in May. The collaboration pairs Somite’s capsule-based data generation platform with industry-leading AMD Instinct™ GPUs, significantly boosting compute power to accelerate training of Somite’s foundation models.

Somite is transforming cell therapy by building large-scale foundation models to rapidly accelerate the development of novel cell therapies, significantly compressing timelines and potentially benefiting millions of patients. The company’s proprietary capsule technology generates differentiation data at approximately one-thousandth the cost of traditional methods, unlocking unprecedented scale and precision for training powerful predictive models.

“We are on the cusp of a true breakthrough in data generation for cell-state transitions. Our capsule-based platform provides dense, causal datasets essential for training transformative foundation models. AMD is uniquely positioned to help us deliver on our promise,” said Dr. Micha Breakstone, Co-Founder and CEO of Somite.ai.

“Biology is experiencing a computational revolution similar to language and vision. Somite is clearly leading the way, and AMD Instinct GPUs are built for the demands of their ambitious models,” said Sagi Paz, Head of AMD Ventures. “We are excited to collaborate with a company converting cutting-edge compute capabilities into meaningful therapies.”

The collaboration will explore optimization of software tools for biological data and joint efforts to develop solutions tailored for next-generation foundation models.

About Somite.ai

Somite.ai is developing AI foundation models for human stem cells to drive novel cell therapies at scale. Somite takes a full-stack approach—generating data at 1,000x lower cost, training large-scale models with unmatched predictive power, and using these models to discover, refine, and optimize high-impact applications in cell therapy. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT (pioneered foundational research on scaling laws), and three National Academy of Science members. Based in Boston and launching operations in January 2024, Somite has raised approximately $60M to date.

Media Contacts
[email protected]

SOURCE Somite Therapeutics